PainReform Ltd.

NasdaqCM PRFX

PainReform Ltd. Free Cash Flow Yield on December 30, 2024: -404.21%

PainReform Ltd. Free Cash Flow Yield is -404.21% on December 30, 2024, a 99.97% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

PainReform Ltd. 52-week high Free Cash Flow Yield is -69.31% on December 13, 2024, which is 82.85% above the current Free Cash Flow Yield.
PainReform Ltd. 52-week low Free Cash Flow Yield is -14,461,269.96% on August 08, 2024, which is -3,577,527.19% below the current Free Cash Flow Yield.
PainReform Ltd. average Free Cash Flow Yield for the last 52 weeks is -4,320,541.68%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NasdaqCM: PRFX

PainReform Ltd.

CEO	Dr. Ehud Geller Ph.D.
IPO Date	Sept. 1, 2020
Location	Israel
Headquarters	65 Yigal Alon Street
Employees	7
Sector	Health Care
Industries Pharmaceuticals Clinical Trials

Description

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Key trends

Past 5 years